TP53 and cancer: As most patients with BE will not progress to cancer, we have investigated additional nucleic acid biomarkers for the Cytosponge, including methylation and p53 mutations to stratify patients according to their risk of progression to cancer.7, 8 Ideally, a single automated platform using nucleic acids (DNA and RNA) extracted from the Cytosponge could be used to diagnose and risk-stratify patients in parallel rather than relying on a 2-step process involving an immunohistochemical biomarker.